scholarly journals Genetic risk scores in adult-onset type 1 diabetes

2018 ◽  
Vol 6 (3) ◽  
pp. 168-169 ◽  
Author(s):  
Richard David Leslie ◽  
Åke Lernmark
2018 ◽  
Vol 6 (3) ◽  
pp. 169
Author(s):  
Nicholas J Thomas ◽  
Samuel E Jones ◽  
Michael N Weedon ◽  
Beverley M Shields ◽  
Andrew T Hattersley ◽  
...  

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 244-OR
Author(s):  
PETER K. YANG ◽  
SANDRA JACKSON ◽  
BRIAN R. CHAREST ◽  
MICHAEL N. WEEDON ◽  
YILING J. CHENG ◽  
...  

2018 ◽  
Vol 50 ◽  
pp. 96-102 ◽  
Author(s):  
Seth A Sharp ◽  
Michael N Weedon ◽  
William A Hagopian ◽  
Richard A Oram

2017 ◽  
Vol 17 (12) ◽  
Author(s):  
Maria J. Redondo ◽  
Richard A. Oram ◽  
Andrea K. Steck

Diabetologia ◽  
2021 ◽  
Author(s):  
Nicholas J. Thomas ◽  
John M. Dennis ◽  
Seth A. Sharp ◽  
Akaal Kaur ◽  
Shivani Misra ◽  
...  

Abstract Aims/hypothesis Among white European children developing type 1 diabetes, the otherwise common HLA haplotype DR15-DQ6 is rare, and highly protective. Adult-onset type 1 diabetes is now known to represent more overall cases than childhood onset, but it is not known whether DR15-DQ6 is protective in older-adult-onset type 1 diabetes. We sought to quantify DR15-DQ6 protection against type 1 diabetes as age of onset increased. Methods In two independent cohorts we assessed the proportion of type 1 diabetes cases presenting through the first 50 years of life with DR15-DQ6, compared with population controls. In the After Diabetes Diagnosis Research Support System-2 (ADDRESS-2) cohort (n = 1458) clinician-diagnosed type 1 diabetes was confirmed by positivity for one or more islet-specific autoantibodies. In UK Biobank (n = 2502), we estimated type 1 diabetes incidence rates relative to baseline HLA risk for each HLA group using Poisson regression. Analyses were restricted to white Europeans and were performed in three groups according to age at type 1 diabetes onset: 0–18 years, 19–30 years and 31–50 years. Results DR15-DQ6 was protective against type 1 diabetes through to age 50 years (OR < 1 for each age group, all p < 0.001). The following ORs for type 1 diabetes, relative to a neutral HLA genotype, were observed in ADDRESS-2: age 5–18 years OR 0.16 (95% CI 0.08, 0.31); age 19–30 years OR 0.10 (0.04, 0.23); and age 31–50 years OR 0.37 (0.21, 0.68). DR15-DQ6 also remained highly protective at all ages in UK Biobank. Without DR15-DQ6, the presence of major type 1 diabetes high-risk haplotype (either DR3-DQ2 or DR4-DQ8) was associated with increased risk of type 1 diabetes. Conclusions/interpretation HLA DR15-DQ6 confers dominant protection from type 1 diabetes across the first five decades of life. Graphical abstract


2018 ◽  
Vol 56 (9) ◽  
pp. 602-605 ◽  
Author(s):  
Andreas Beyerlein ◽  
Ezio Bonifacio ◽  
Kendra Vehik ◽  
Markus Hippich ◽  
Christiane Winkler ◽  
...  

BackgroundProgression time from islet autoimmunity to clinical type 1 diabetes is highly variable and the extent that genetic factors contribute is unknown.MethodsIn 341 islet autoantibody-positive children with the human leucocyte antigen (HLA) DR3/DR4-DQ8 or the HLA DR4-DQ8/DR4-DQ8 genotype from the prospective TEDDY (The Environmental Determinants of Diabetes in the Young) study, we investigated whether a genetic risk score that had previously been shown to predict islet autoimmunity is also associated with disease progression.ResultsIslet autoantibody-positive children with a genetic risk score in the lowest quartile had a slower progression from single to multiple autoantibodies (p=0.018), from single autoantibodies to diabetes (p=0.004), and by trend from multiple islet autoantibodies to diabetes (p=0.06). In a Cox proportional hazards analysis, faster progression was associated with an increased genetic risk score independently of HLA genotype (HR for progression from multiple autoantibodies to type 1 diabetes, 1.27, 95% CI 1.02 to 1.58 per unit increase), an earlier age of islet autoantibody development (HR, 0.68, 95% CI 0.58 to 0.81 per year increase in age) and female sex (HR, 1.94, 95% CI 1.28 to 2.93).ConclusionsGenetic risk scores may be used to identify islet autoantibody-positive children with high-risk HLA genotypes who have a slow rate of progression to subsequent stages of autoimmunity and type 1 diabetes.


Diabetologia ◽  
2007 ◽  
Vol 50 (11) ◽  
pp. 2276-2279 ◽  
Author(s):  
Y. M. Cho ◽  
J. T. Kim ◽  
K. S. Ko ◽  
B. K. Koo ◽  
S. W. Yang ◽  
...  

Endocrine ◽  
2015 ◽  
Vol 49 (3) ◽  
pp. 693-702 ◽  
Author(s):  
Ananta Poudel ◽  
Omid Savari ◽  
Deborah A. Striegel ◽  
Vipul Periwal ◽  
Jerome Taxy ◽  
...  

2016 ◽  
Vol 40 (2) ◽  
pp. 164-169 ◽  
Author(s):  
Janet Jull ◽  
Holly O. Witteman ◽  
Judi Ferne ◽  
Manosila Yoganathan ◽  
Dawn Stacey

Sign in / Sign up

Export Citation Format

Share Document